Farmakokinetyka nieliniowa: Przegląd

Nonlinear pharmacokinetics occurs when drug saturation affects elimination pathways. Common causes include saturation of plasma protein-binding sites, carrier-mediated transport systems, hepatic metabolism, and active renal tubular secretion. Competition with other drugs sharing the same enzyme or carrier system can also trigger nonlinearity. Additionally, pathophysiological changes like renal nephrotoxicity can alter drug excretion and accumulation.

In first-order kinetics, drug elimination rate is directly proportional to drug concentration. Saturation kinetics occurs when binding sites or metabolic enzymes become saturated, causing elimination to become dose-dependent. At higher doses, the elimination half-life increases and the area under the curve becomes non-proportional to the bioavailable drug amount, unlike the predictable linear relationship in first-order kinetics.

When drug dose increases, saturation of metabolic enzymes or binding sites limits the body's elimination capacity. This causes the elimination half-life and apparent elimination rate constant to increase with dose. The nonlinear pharmacokinetics dependence of elimination half-life and dose clearance means higher doses persist longer in the body, potentially increasing toxicity risk and requiring careful dose adjustments.

Nonlinear pharmacokinetics is detected by determining steady-state plasma concentration at different doses and measuring key pharmacokinetic parameters like elimination half-life and systemic clearance. Plotting plasma level-time curves for various doses reveals nonlinearity when curves show non-parallel slopes. If curves exhibit parallel slopes, the drug follows dose-independent kinetics, indicating linear behavior.

When drug dose increases, the composition or ratio of a drug's metabolites may change due to saturation of specific metabolic pathways. At higher doses, some enzyme systems become saturated while others remain active, altering which metabolic routes predominate. This shift in metabolite profile can affect the drug's pharmacological effects and safety profile, making dose-dependent metabolite monitoring important for patient safety.

Drugs exhibiting nonlinear pharmacokinetics have non-proportional dose-to-plasma concentration relationships, making standard dosing unreliable. Incorrect dosing can significantly increase toxic outcomes because small dose increases may cause disproportionately large plasma concentration increases. Individualized therapy with careful monitoring and dose adjustments ensures therapeutic efficacy while minimizing adverse effects and toxicity risk for these dose-dependent drugs.

When plasma protein-binding sites saturate, the unbound drug fraction increases, raising the drug's active concentration in the bloodstream. This saturation can increase the drug's pharmacological effects and toxicity risk. For example, high concentrations of phenylbutazone increase the unbound drug fraction, elevating adverse effect risk. Understanding nonlinear pharmacokinetics bioavailability and protein-drug binding is crucial for predicting drug behavior at higher doses.